Trial results presented at US oncology conference suggest ribociclib could be gamechanging and boost survival rate significantly
Thousands of women with the world’s most common form of breast cancer could benefit from a blockbuster drug that helps them live longer and cuts the risk of the disease returning by a quarter.
More than 2 million people globally are diagnosed each year with the disease, which is the world’s most prevalent cancer. Although treatments have improved in recent decades, many patients will later experience the cancer returning. If a recurrence does occur, it is often at a more advanced stage.
About Author
More Stories
52 tiny annoying problems, solved! (Because when you can’t control the big stuff, start small)
Chinese tech firms freeze AI tools in crackdown on exam cheats
US arrests another Chinese scientist for allegedly smuggling biological material